Non-Hodgkins Lymphoma Archives -

A history of blood cancer treatment

Eloise McLennan A history of..., blood cancer, bone marrow transplant, breakthroughs, CAR-T therapies, cell therapies, chemotherapy, cord blood, immunology, leukaemia, lymphoma, melanoma, Non-Hodgkins Lymphoma 0 Comment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to

A history of blood cancer treatment

https://pharmaphorum.com/oncology/a-history-of-blood-cancer-treatment/

News/ News/ Oncology

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Phil Taylor CHMP, ema, Gilead Sciences, Kite Pharma, mantle cell lymphoma, Non-Hodgkins Lymphoma 0 Comment

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

https://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/

News/ News/ News/ Oncology/ Patients

Real-world data backs Kymriah’s safety profile, says Novartis

Phil Taylor acute lymphoblastic leukaemia, Haematology, Kymriah, Non-Hodgkins Lymphoma, Novartis, real world data 0 Comment

With more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

News/ News/ Oncology

Early data from Roche’s NHL drug mosunetuzumab steals the show at ASH

Richard Staines cancer, Non-Hodgkins Lymphoma, Roche 0 Comment

There’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising

Early data from Roche’s NHL drug mosunetuzumab steals the show at ASH

https://pharmaphorum.com/news/early-data-from-roches-mosunetuzumab-steals-the-show-at-ash/

News

Celgene bags FDA okay for Revlimid combo in lymphoma

Phil Taylor Celgene, Non-Hodgkins Lymphoma, Revlimid, Rituxan 0 Comment

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use

Celgene bags FDA okay for Revlimid combo in lymphoma

https://pharmaphorum.com/news/celgene-bags-fda-okay-for-revlimid-combo-in-lymphoma/

News/ News/ Oncology

EU approves Kyowa Kirin’s drug for rare lymphoma

Joy Persaud cancer, Kyowa Kirin, Non-Hodgkins Lymphoma 0 Comment

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is

EU approves Kyowa Kirin’s drug for rare lymphoma

https://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/

News/ News/ Oncology

Celltrion/Teva Rituxan biosimilar edges closer to US approval

Richard Staines cancer, Celltrion, Non-Hodgkins Lymphoma, Roche, Teva 0 Comment

It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in

Celltrion/Teva Rituxan biosimilar edges closer to US approval

https://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/

Cancer/ News/ R&D

Great news for Kite after CAR-T success in cancer patients

Andrew McConaghie CAR T, Kite Pharma, NHL, Non-Hodgkins Lymphoma 0 Comment

Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the

Great news for Kite after CAR-T success in cancer patients

https://pharmaphorum.com/news/good-news-kites-car-t-drug-lymphoma/

Trending

Non-Hodgkins Lymphoma

Login